CO2023002114A2 - Composiciones de vacunas multivalentes y usos de las mismas - Google Patents

Composiciones de vacunas multivalentes y usos de las mismas

Info

Publication number
CO2023002114A2
CO2023002114A2 CONC2023/0002114A CO2023002114A CO2023002114A2 CO 2023002114 A2 CO2023002114 A2 CO 2023002114A2 CO 2023002114 A CO2023002114 A CO 2023002114A CO 2023002114 A2 CO2023002114 A2 CO 2023002114A2
Authority
CO
Colombia
Prior art keywords
compositions
expec
methods
multivalent vaccines
coli
Prior art date
Application number
CONC2023/0002114A
Other languages
English (en)
Inventor
Jan Theunis Poolman
Kellen Cristhina Fae
Michal Sarnecki
Jeroen Geurtsen
Darren Robert Abbanat
Bart Gustaaf M Spiessens
Frank Germaine F Struyf
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of CO2023002114A2 publication Critical patent/CO2023002114A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen composiciones y métodos para inducir una respuesta inmunitaria contra la Escherichia coli patógena extraintestinal (ExPEC) para proporcionar de este modo una protección inmunitaria contra las enfermedades asociadas a la ExPEC. En particular, se describen composiciones y métodos para utilizar conjugados del polisacárido de antígeno O75 de E. coli unidos de manera covalente a una proteína portadora para la prevención de la enfermedad invasiva por ExPEC.
CONC2023/0002114A 2020-09-17 2023-02-27 Composiciones de vacunas multivalentes y usos de las mismas CO2023002114A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063079734P 2020-09-17 2020-09-17
EP21154782 2021-02-02
US202163191471P 2021-05-21 2021-05-21
PCT/IB2021/058485 WO2022058945A1 (en) 2020-09-17 2021-09-17 Multivalent vaccine compositions and uses thereof

Publications (1)

Publication Number Publication Date
CO2023002114A2 true CO2023002114A2 (es) 2023-03-07

Family

ID=77801756

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0002114A CO2023002114A2 (es) 2020-09-17 2023-02-27 Composiciones de vacunas multivalentes y usos de las mismas

Country Status (17)

Country Link
US (1) US20220088165A1 (es)
EP (1) EP4213870A1 (es)
JP (1) JP7481585B2 (es)
KR (1) KR20230043157A (es)
CN (1) CN115803087A (es)
AU (1) AU2021342797B2 (es)
BR (1) BR112023004819A2 (es)
CA (1) CA3190820A1 (es)
CL (1) CL2023000740A1 (es)
CO (1) CO2023002114A2 (es)
EC (1) ECSP23019295A (es)
IL (2) IL308201A (es)
MX (1) MX2023003169A (es)
PE (1) PE20231385A1 (es)
TW (1) TW202227128A (es)
UY (1) UY39428A (es)
WO (1) WO2022058945A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3134045A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
PE20212265A1 (es) 2019-03-18 2021-11-30 Janssen Pharmaceuticals Inc Bioconjugados de antigenos-polisacaridos de e. coli, metodos de produccion y metodos de utilizacion de los mismos

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0911036A3 (en) 1992-02-11 2001-05-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
JP3755890B2 (ja) 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
ATE280235T1 (de) 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
NZ274376A (en) 1993-09-22 1997-11-24 Jackson H M Found Military Med Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs
EP0814833B1 (en) 1995-03-22 2003-05-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6491919B2 (en) 1997-04-01 2002-12-10 Corixa Corporation Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
ES2227825T3 (es) 1997-04-01 2005-04-01 Corixa Corporation Composiciones inmunologicas aduvantes acuosas de monofosforil lipido a.
TR200101055T2 (tr) 1998-10-16 2001-09-21 Smithkline Beecham Biologicals S.A. Adjuvan sistemler ve aşılar
WO2001078777A2 (en) 2000-04-13 2001-10-25 Mossman, Sally Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
US6676958B2 (en) 2001-06-19 2004-01-13 Advanced Bioadjuvants, Llc Adjuvant composition for mucosal and injection delivered vaccines
WO2003074687A1 (en) 2002-03-07 2003-09-12 Eidgenössische Technische Hochschule Zürich System and method for the production of recombinant glycosylated proteins in a prokaryotic host
CN101360831B (zh) 2005-05-11 2013-07-10 Eth苏黎世公司 来自原核细胞的重组n-糖基化蛋白
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
WO2007109812A2 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
CA2711503A1 (en) 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
JP5782258B2 (ja) 2008-02-20 2015-09-24 グリコヴァキシン アーゲー 原核細胞由来の組換えｎ−グリコシル化タンパク質から作製したバイオコンジュゲート
RU2560182C2 (ru) 2009-06-05 2015-08-20 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
KR101742406B1 (ko) 2012-08-16 2017-05-31 화이자 인코포레이티드 당접합 공정 및 조성물
CA2883000A1 (en) 2012-09-10 2014-03-13 Glycovaxyn Ag Bioconjugates comprising modified antigens and uses thereof
US20150267207A1 (en) 2012-10-12 2015-09-24 Glycovaxyn Ag Methods of host cell modification
CN106177933B (zh) 2012-12-20 2020-09-29 辉瑞公司 免疫原性组合物
MX354057B (es) 2013-05-18 2018-02-09 The Regents Of The Univ Of California Star Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón".
CN103495161B (zh) 2013-10-08 2019-06-18 江苏康泰生物医学技术有限公司 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法
SG11201602546RA (en) 2013-10-11 2016-04-28 Glycovaxyn Ag Methods of host cell modification
EA201690859A1 (ru) 2013-12-04 2016-11-30 Гликоваксин Аг Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli
SG11201606889PA (en) 2014-02-24 2016-09-29 Glycovaxyn Ag Novel polysaccharide and uses thereof
ES2939470T3 (es) 2014-04-17 2023-04-24 Glaxosmithkline Biologicals Sa Células hospedadoras modificadas y usos de las mismas
CN105695497B (zh) 2014-11-27 2019-09-24 中国人民解放军军事医学科学院生物工程研究所 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用
ES2907211T3 (es) 2014-12-30 2022-04-22 Glaxosmithkline Biologicals Sa Composiciones y métodos para la glicosilación de proteínas
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
AR109621A1 (es) * 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
JP2022513458A (ja) 2018-12-12 2022-02-08 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
CA3134045A1 (en) * 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Methods of producing bioconjugates of e. coli o-antigen polysaccharides, compositions thereof, and methods of use thereof
PE20212265A1 (es) * 2019-03-18 2021-11-30 Janssen Pharmaceuticals Inc Bioconjugados de antigenos-polisacaridos de e. coli, metodos de produccion y metodos de utilizacion de los mismos

Also Published As

Publication number Publication date
CL2023000740A1 (es) 2023-09-29
IL301248A (en) 2023-05-01
IL308201A (en) 2024-01-01
US20220088165A1 (en) 2022-03-24
AU2021342797B2 (en) 2024-02-08
PE20231385A1 (es) 2023-09-12
MX2023003169A (es) 2023-03-27
CA3190820A1 (en) 2022-03-24
IL301248B1 (en) 2023-12-01
ECSP23019295A (es) 2023-04-28
IL301248B2 (en) 2024-04-01
TW202227128A (zh) 2022-07-16
BR112023004819A2 (pt) 2023-04-18
AU2021342797A1 (en) 2023-02-16
JP7481585B2 (ja) 2024-05-10
WO2022058945A1 (en) 2022-03-24
UY39428A (es) 2022-03-31
CN115803087A (zh) 2023-03-14
KR20230043157A (ko) 2023-03-30
EP4213870A1 (en) 2023-07-26
JP2023539943A (ja) 2023-09-20

Similar Documents

Publication Publication Date Title
ECSP23019295A (es) Composiciones de vacunas multivalentes y usos de las mismas
CO2017011245A2 (es) Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos
BR112018007812A2 (pt) polissacarídeo capsular, processo para preparar um polissacarídeo capsular e para fabricar uma vacina, composição imunogênica, vacina, métodos para tratamento ou prevenção de uma infecção, para imunizar um hospedeiro humano e para induzir uma resposta imune, e, uso de uma composição imunogênica.
NI202000040A (es) Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos
BR112018003469A2 (pt) composição, método para induzir uma resposta imune a e. coli patogênica extraintestinal, e, processo para produzir uma composição.
AR100859A1 (es) Polisacáridos y sus usos
CO2019003949A2 (es) Formulaciones de vacunas de glicoconjugados de expec
CY1111916T1 (el) Εμβολιο ζωντανου εξασθενημενου ροταϊου για χορηγηση απο του στοματος
NI202100050A (es) Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
AR118389A1 (es) Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización
CA2922320A1 (en) Enhanced photochemical internalisation using a tlr ligand
CO2021003931A2 (es) Dosis unitaria de vacuna contra el dengue y administración de esta
CY1123583T1 (el) Ανοσογονος συνθεση για χρηση στη θεραπεια
PE20211095A1 (es) Composiciones de escherichia coli y metodos de estas
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
EA202091690A1 (ru) Иммуногенная композиция, содержащая стафилококковые антигены
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
AR079375A1 (es) Soluciones de rehidratacion oral que comprenden dextrosa. metodo de preparacion.
CO2021012240A2 (es) Conjugados de hialuronano y usos de estos
AR123545A1 (es) Composiciones de vacunas multivalentes y usos de las mismas
AR105793A1 (es) Métodos y composiciones para protección inmunológica contra e. coli patogénica extraintestinal
AR087811A1 (es) Vacuna contra el staphylococcus aureus
BR112019003609A2 (pt) remédio para profilaxia de leucemia bovina e método de uso.
WO2024107729A3 (en) Multivalent vaccine compositions and uses thereof
Bandyopadhaya et al. Toll-like receptor (TLR) and nucleotide-binding oligomerization domain (NOD) signaling during Vibrio cholerae infection